All Updates

All Updates

icon
Filter
Partnerships
CENTOGENE and Takeda extend partnership to provide diagnostic testing for LSDs
Precision Medicine
Apr 11, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
Precision Medicine

Precision Medicine

Apr 11, 2023

CENTOGENE and Takeda extend partnership to provide diagnostic testing for LSDs

Partnerships

  • German commercial-stage diagnostic company Centogene N.V. has extended its partnership with Japanese pharma company Takeda Pharmaceuticals for one year to provide diagnostic testing for Lysosomal Storage Disorders (LSDs), including Fabry disease, Gaucher disease, and Hunter syndrome. 

  • The partnership aims to enhance patient access to rapid and reliable diagnostics for LSDs by leveraging CENTOGENE's targeted diagnostic portfolio, network of over 30,000 active physicians, and the CENTOGENE Biodatabank, which currently contains data for approximately 700,000 patients representing over 120 highly diverse countries. The partnership will continue to play a vital role in the expansion of Takeda's enzyme replacement treatments and provide life-changing answers to underserved patient communities. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.